June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Results from Event-free survival (EFS) in Matterhorn – Memorial Sloan Kettering Cancer Center
Jun 1, 2025, 04:49

Results from Event-free survival (EFS) in Matterhorn – Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:

“Plenary session alert: MSK gastrointestinal oncologist Dr. Yelena Janjigian.
Will share results from “Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)” TODAY at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Date: 6/1 at 3:13pm CT.”

Memorial Sloan Kettering announced that Dr. Yelena Janjigian will present results from the MATTERHORN phase 3 trial during a plenary session at ASCO. The study evaluates event-free survival for durvalumab in combination with FLOT chemotherapy in patients with resectable gastric or gastroesophageal junction cancer.

More posts featuring Memorial Sloan Kettering Cancer Center.